Altamira Therapeutics Ltd. (CYTO) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Altamira Therapeutics Ltd...

    NASDAQ: CYTO · Real-Time Price · USD
    0.30
    0.00 (0.00%)
    At close: Jan 16, 2025, 10:00 PM

    Altamira Therapeutics Income Statement

    Financials in CHF. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 305.62K 63.88K
    Cost of Revenue
    		 n/a 1.44M 2.24M
    Gross Profit
    		 n/a -1.14M -2.18M
    Operating Income
    		 -5.92M -26.13M -17.1M
    Interest Income
    		 730.2K 969.00 3.22K
    Pretax Income
    		 -7.27M -26.54M -17.37M
    Net Income
    		 -7.27M -26.53M -17.39M
    Selling & General & Admin
    		 3.12M 5.9M 6.39M
    Research & Development
    		 3.04M 19.68M 8.94M
    Other Expenses
    		 n/a -586.73K -409.93K
    Operating Expenses
    		 6.54M 24.99M 14.92M
    Interest Expense
    		 n/a 911.87K 189.69K
    Selling & Marketing Expenses
    		 15.35K 2.38M 1.5M
    Cost & Expenses
    		 6.54M 26.44M 17.16M
    Income Tax Expense
    		 n/a -10.33K 21.62K
    Shares Outstanding (Basic)
    		 491K 45.54K 33.12K
    Shares Outstanding (Diluted)
    		 491.26K 45.54K 33.12K
    EPS (Basic)
    		 -14.81 -582.58 -525.13
    EPS (Diluted)
    		 -14.8 -582.58 -525.13
    EBITDA
    		 -1.35M -17.64M -6.72M
    EBIT
    		 n/a -17.76M -6.79M
    Depreciation & Amortization
    		 5.92M 118.89K 76.36K

    Add to Watchlist